Curcumin reverses cisplatin resistance in cisplatin-resistant lung caner cells by inhibiting FA/BRCA pathway

详细信息    查看全文

• 作者：Ping Chen ; Jian Li ; He-Guo Jiang ; Ting Lan ; Yong-Chang Chen
• 关键词：Curcumin ; Cisplatin ; Lung cancer cells ; FA/BRCA pathway ; DNA repair ; Resistance
• 刊名：Tumor Biology
• 出版年：2015
• 出版时间：May 2015
• 年：2015
• 卷：36
• 期：5
• 页码：3591-3599
• 全文大小：3,334 KB
• 参考文献：1.Spira SG, Silvestri GA. The treatment of advanced non-small cell lung cancer. Curr Opin Pulm Med. 2005;11:287鈥?1.View Article
  2.Massarelli E, Herbst RS. Use of novel second-line target therapies in non-small cell lung cancer. Semin Oncol. 2006;33 suppl 1:s9鈥?6.View Article PubMed
  3.Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379鈥?2.View Article PubMed
  4.Resell R, Cecere F, Santarpia M, Noemi R, Miquel T. Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol. 2006;6:323鈥?1.View Article
  5.Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res. 2001;478:23鈥?3.View Article PubMed
  6.Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7:573鈥?4.View Article PubMed
  7.Kennedy RD, D鈥橝ndrea AD. DNA repair pathway in clinical practice: lesions from pediatric cancer susceptibility syndromes. J Clin Oncol. 2006;24:3799鈥?08.View Article PubMed
  8.Kim H, D鈥橝ndrea AD. Regulation of DNA Cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev. 2012;26:1393鈥?08.View Article PubMed Central PubMed
  9.Auerbach AD. Fanconi anemia and its diagnosis. Mutat Res. 2009;668:4鈥?0.View Article PubMed Central PubMed
  10.Alan D. The Fanconi anemia and breast susceptibility pathway. N Engl J Med. 2010;362:1909鈥?9.View Article PubMed Central
  11.Kee Y, D鈥橝ndrea AD. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev. 2010;24:1680鈥?4.View Article PubMed Central PubMed
  12.Su X, Huang J. The Fanconi anemia pathway and DNA interstrand cross-link repair. Protein Cell. 2011;2:704鈥?1.View Article PubMed
  13.Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med. 2003;9:568鈥?4.View Article PubMed
  14.Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA-mutated cancers. Nature. 2008;451:1116鈥?0.View Article PubMed Central PubMed
  15.Jagtap S, Meganathan K, Wagh V, Winkler J, Hescheler J, Sachinidis A. Chemoprotective mechanism of the natural compounds, epigallocatechin-3-O-gallate, quercetin and curcumin against cancer and cardiovascular diseases. Curr Med Chem. 2009;16:1451鈥?2.View Article PubMed
  16.Shishodia S, Chalurvedi MM, Aggarwal BB. Role of curcumin in cancer therapy. Curr Probl Cancer. 2007;31:243鈥?05.View Article PubMed
  17.Ye MX, Li Y, Yin H, Zhang J. Curcumin: updated molecular mechanisms and intervention targets in human lung cancer. Int J Mol Sci. 2012;13:3959鈥?8.View Article PubMed Central PubMed
  18.Duarte VM, Han E, Veena MS, Salvado A, Suh JD, Liang LJ, et al. Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of IKK尾 protein of the NF魏B pathway. Mol Cancer Ther. 2010;9:2665鈥?5.View Article PubMed Central PubMed
  19.Xu XB, Chen B, Liu WY. Curcumin inhibits the invasion of thyroid cancer cells via down-regulation of PI3K/kt signaling pathway. Gene. 2014;546:226鈥?2.View Article PubMed
  20.Zang S, Liu T, Shi J, Qiao L. Curcumin: a promising agent targeting cancer stem cells. Anticancer Agents Med Chem. 2014;14:787鈥?2.View Article PubMed
  21.Chirnomas D, Taniguchi T, de la Vaga M, Vaidya AP, Vasserman M, Hartman A-R, et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther. 2006;5:952鈥?1.View Article PubMed
  22.Xiao H, Xiao Q, Zhang K, Zuo X, Shresthan UK. Reversal of multidrug resistance by curcumin through FA/BRCA pathway in multiple myeloma cell line MOLP-2/R. Ann Hematol. 2010;89:399鈥?04.View Article PubMed
  23.Shao Z-M, Shen Z-Z, Liu C-H, Sartippour MR, Heber D, Nguyen M. Curcumin exerts multiples suppressive effects on human breast carcinoma cells. Int J Cancer. 2002;98:234鈥?0.View Article PubMed
  24.Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood. 2005;106:698鈥?05.View Article PubMed Central PubMed
  25.van der Heijden MS, Brody JR, Gallemier E, Cunningham SC, Dezentje DA, Shen D, et al. Function defects in the Fanconi anemia pathway in pancreatic cancer cells. Am J Pathol. 2004;165:651鈥?.View Article PubMed Central PubMed
  26.Burkitt K, Ljungman M. Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines. Cancer Lett. 2007;8:131鈥?.View Article
  27.Zhang J, Wang X, Lin C-J, Conch FJ, Fei P. Altered expression of FANCL confers mitomycin C sensitivity in calu-6 lung cancer cells. Cancer Biol Ther. 2006;5:1632鈥?.View Article PubMed
  28.Burkitt K, Ljurgman M. Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitized head and neck cancer cells to cisplatin. Mol Cancer. 2008;7:24.View Article PubMed Central PubMed
  29.Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, Boulware D, et al. Targeting the Fanconi anemial BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res. 2009;69:9367鈥?5.View Article PubMed
  30.Chen J, Dexheimer TS, Ai Y, Liang G, Villamil MA, Inglese J, et al. Selective and cell-active inhibitors of the USP1/UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. Chem Biol. 2011;18:1390鈥?00.View Article PubMed Central PubMed
  31.Kee Y, Huang M, Chang S, Moreau LA, Park E, Smith PG, et al. Inhibition of the Nedd8 system sensitive cells to DNA interstrand cross-linking agents. Mol Cancer Res. 2012;10:369鈥?7.View Article PubMed Central PubMed
  32.Litan R, Gupta R, Brosh Jr RM, Cantor SB. BRCA-FA pathway as a target for anti-tumor drugs. Anticancer Agents Med Chem. 2008;8:423鈥?0.
  33.Hucl T, Gallmeier E. DNA repair: exploiting the Fanconi anemia pathway as a potential therapeutic target. Physiol Res. 2011;60:453鈥?5.PubMed
  34.Shukl P, Solank A, Ghos K, Vundinit BR. DNA interstrand cross-link repair: understanding role of Fanconi anemia pathway and therapeutic implications. Eur J Haematol. 2013;9:381鈥?3.View Article
  35.Kunnunakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling protein. Cancer Lett. 2008;269:199鈥?55.View Article
  36.Yu LL, Wu JG, Dai HG, Si JM. Curcumin reverses chemoresistance of human gastric cancer cells by downregulating the NF-Kappa B transcritption factor. Oncol Rep. 2011;26:1197鈥?03.PubMed
  37.Jana NR, Diskshit P, Goswami A, Nukina N. Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J Biol Chem. 2004;219:11680鈥?.View Article
  38.Jacquemont C, Taniguchi T. Proteasome function is required for DNA damage response and Fanconi anemia pathway activation. Cancer Res. 2007;67:7395鈥?05.View Article PubMed
  
• 作者单位：Ping Chen (1)
  Jian Li (1)
  He-Guo Jiang (1)
  Ting Lan (2)
  Yong-Chang Chen (2)
  
  1. Department of Pulmonary Medicine, Affiliated Hospital of Jiangsu University, 438 North Jiefang Street, Zhenjiang, 212001, China
  2. Institute of Medical Science, Jiangsu University, Zhenjian, China
  
• 刊物主题：Cancer Research;
• 出版者：Springer Netherlands
• ISSN：1423-0380

文摘

Cisplatin (DDP) is the most widely used chemotherapy agent for treatment of malignancies including lung cancer. However, the effectiveness of DDP is often weakened by acquired resistance of tumor cells. DDP kills cancer cells primarily by creating intrastrand and interstrand DNA cross-links, which block DNA replication. The Fanconi anemia (FA)/BRCA pathway is a DNA cross-link damage repair pathway, which regulates cellular resistance to DNA cross-link agents, such as DDP. Some study has shown that natural compound curcumin sensitize human ovarian and breast cancer cells to DDP. However, whether curcumin may reverse resistance to DDP in DDP-resistant lung cancer cells has not been understood. In this study, we showed that curcumin enhanced the proliferation inhibitory effect of DDP and promote DDP-induced apoptosis in A549/DDP cells (DDP-resistant lung adenocarcinoma cells). Moreover, we observed that FA/BRCA pathway DNA damage repair processes, such as DDP-induced FANCD₂ monoubiquitination and nuclear foci formation were downregulated in the presence of curcumin, suggesting that curcumin enhanced sensitivity to DDP in A549/DDP cells through the inhibition of FA/BRCA pathway. Furthermore, the calculation of q value and apoptosis analyses revealed that curcumin in combination with DDP could exert a synergistic cytotoxic effect in A549/DDP cells, further demonstrating that curcumin can reverse cisplatin resistance of A549/DDP cells. In conclusion, by suppressing the FA/BRCA pathway DNA repair, curcumin potentiates DDP-induced proliferation inhibitory effect and apoptosis in A549/DDP cell, indicating that curcumin may serve as a chemosensitizer to cross-link-inducing anticancer drugs DDP.